EPS for Summit Therapeutics plc (SMMT) Expected At $-0.73

December 8, 2017 - By Louis Casey

 EPS for Summit Therapeutics plc (SMMT) Expected At $ 0.73

Analysts expect Summit Therapeutics plc (NASDAQ:SMMT) to report $-0.73 EPS on December, 21.They anticipate $0.28 EPS change or 62.22 % from last quarter’s $-0.45 EPS. After having $1.10 EPS previously, Summit Therapeutics plc’s analysts see -166.36 % EPS growth. The stock increased 0.09% or $0.01 during the last trading session, reaching $11.46. About 7,707 shares traded. Summit Therapeutics plc (NASDAQ:SMMT) has risen 33.22% since December 8, 2016 and is uptrending. It has outperformed by 16.52% the S&P500.

Summit Therapeutics plc (NASDAQ:SMMT) Ratings Coverage

Among 6 analysts covering Summit Therapeutic (NASDAQ:SMMT), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Summit Therapeutic had 9 analyst reports since August 19, 2015 according to SRatingsIntel. H.C. Wainwright maintained Summit Therapeutics plc (NASDAQ:SMMT) on Thursday, July 6 with “Buy” rating. Oppenheimer maintained Summit Therapeutics plc (NASDAQ:SMMT) on Wednesday, August 19 with “Buy” rating. The firm has “Buy” rating by H.C. Wainwright given on Friday, December 1. The rating was maintained by Canaccord Genuity on Thursday, June 15 with “Buy”. The rating was maintained by Oppenheimer on Thursday, June 22 with “Buy”. H.C. Wainwright initiated Summit Therapeutics plc (NASDAQ:SMMT) rating on Friday, September 16. H.C. Wainwright has “Buy” rating and $26 target. RBC Capital Markets maintained Summit Therapeutics plc (NASDAQ:SMMT) on Wednesday, November 16 with “Outperform” rating. The firm earned “Hold” rating on Tuesday, September 1 by Zacks. The firm earned “Buy” rating on Tuesday, June 21 by Janney Capital.

Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat genetic and infectious diseases in the United Kingdom and North America. The company has market cap of $165.70 million. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy and the infectious disease Clostridium difficile infection (CDI). It currently has negative earnings. The companyÂ’s lead DMD product candidate is ezutromid, an orally administered small molecule, which is in Phase II clinical trial in patients with DMD; and lead CDI product candidate is ridinilazole, an orally administered small molecule antibiotic that has completed Phase II clinical trials for the treatment of CDI disease.

More news for Summit Therapeutics plc (NASDAQ:SMMT) were recently published by: Marketwatch.com, which released: “Summit Therapeutics PLC ADR” on April 22, 2011. Marketwatch.com‘s article titled: “Summit Therapeutics stock surges 50% on news of licensing deal with Sarepta” and published on October 04, 2016 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.